Tags: Oryzon Genomics


ADDF Invests $300,000 to Support Phase 2 Clinical Trial of Epigenetic Therapy

A new investment of $300,000 in Oryzon Genomics continues our support of its groundbreaking epigenetic drug ORY-2001.


Closing in on a Cure: Oryzon Genomics and ORY-2001

Discover ORY-2001, a revolutionary epigenetic therapy for Alzheimer's disease being developed by Oryzon Genomics in Barcelona, Spain. 


Top Five Alzheimer’s Advances in 2016

In 2016, we made great progress toward finding drugs to prevent and treat Alzheimer’s, as our top five advances demonstrate.


Striding Toward $100 Million on Giving Tuesday

Since 1998, the ADDF has invested $97 million in critical research and—with your #GivingTuesday donation—we will reach $100 million this year.


Advancing Epigenetics: A New Approach to Treating Alzheimer’s Disease

Dr. Howard Fillit discusses epigenetic treatments, one of the newest and most promising areas of our portfolio.